{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T05:26:35Z","timestamp":1781760395610,"version":"3.54.5"},"reference-count":33,"publisher":"American Society of Hematology","issue":"5","license":[{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3,12]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors (ICIs) have demonstrated remarkable response rates in relapsed or refractory Hodgkin lymphoma (HL). Still, most patients eventually progress. Patterns of progression after ICIs are not well described and are essential to defining the role of local therapies in combination with ICIs. We identified patients who received ICIs for HL between 2013 and 2022. Fludeoxyglucose-18 positron emission tomography (FDG-PET) before initiating ICI and at progression on\/after ICI were reviewed, and areas of active HL were recorded. An exploratory analysis of treatable progression included patients with \u22645 sites of disease on pre-ICI FDG-PET and progression only at pre-ICI sites. Ninety patients were identified; 69 had complete records, and of these, 32 (52%) had relapsed at ICI initiation, 17 (25%) were refractory, and 16 (23%) received ICI as first-line therapy. Forty-five of 69 patients had \u22645 sites of disease (limited) on pre-ICI FDG-PET. Patients with &amp;gt;5 sites of disease had a higher risk of progression, and every site of disease &amp;gt;5 sites conferred an additional 1.2x higher chance of progression. At a median follow-up of 4.0 years, 41 of 69 patients had progressed on\/after ICIs (cumulative incidence 66.4%), and of these, 22\u00a0of 41 patients progressed only at pre-ICI sites (cumulative incidence 39.4%). In an exploratory analysis, the cumulative incidence of a treatable progression among 45 patients with limited disease was 34%. The cumulative incidence of any progression among this cohort was 58.9%. More than one-third of patients with limited disease before ICIs experienced progression only at pre-ICI sites of disease. These patients could be candidates for radiation during or after ICIs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011533","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T16:59:20Z","timestamp":1704992360000},"page":"1250-1257","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Patterns of progression after immune checkpoint inhibitors for Hodgkin lymphoma: implications for radiation therapy"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8653-1045","authenticated-orcid":false,"given":"Jessica F.","family":"Burlile","sequence":"first","affiliation":[{"name":"1Department of Radiation Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey M.","family":"Frechette","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Breen","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6536-1291","authenticated-orcid":false,"given":"Steven R.","family":"Hwang","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra S.","family":"Higgins","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne N.","family":"Nedved","sequence":"additional","affiliation":[{"name":"3Department of Pharmacy, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S.","family":"Harmsen","sequence":"additional","affiliation":[{"name":"4Department of Biostatistics and Health Sciences Research, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3193-4565","authenticated-orcid":false,"given":"Sydney D.","family":"Pulsipher","sequence":"additional","affiliation":[{"name":"4Department of Biostatistics and Health Sciences Research, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4215-6500","authenticated-orcid":false,"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana N.","family":"Micallef","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2312-5418","authenticated-orcid":false,"given":"Bradford S.","family":"Hoppe","sequence":"additional","affiliation":[{"name":"5Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Habermann","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gita","family":"Thanarajasingam","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick B.","family":"Johnston","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Inwards","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8358-5953","authenticated-orcid":false,"given":"N. Nora","family":"Bennani","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7458-1504","authenticated-orcid":false,"given":"Jennifer L.","family":"Peterson","sequence":"additional","affiliation":[{"name":"5Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J.","family":"Stish","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Rule","sequence":"additional","affiliation":[{"name":"6Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott C.","family":"Lester","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,3,1]]},"reference":[{"issue":"5","key":"2024031115352811800_bib1","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.ijrobp.2018.01.011","article-title":"The role of radiation therapy in patients with relapsed or refractory Hodgkin lymphoma: guidelines from the International Lymphoma Radiation Oncology Group","volume":"100","author":"Constine","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"21","key":"2024031115352811800_bib2","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A\u00a0prognostic score for advanced Hodgkin\u2019s disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2024031115352811800_bib3","first-page":"1384","article-title":"Treatment of Hodgkin lymphoma relapsed after autologous stem cell transplantation","volume":"9","author":"Domingo-Dom\u00e8nech","year":"2020","journal-title":"J\u00a0Clin Med"},{"issue":"14","key":"2024031115352811800_bib4","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the Multicohort Single-Arm Phase II CheckMate 205 Trial","volume":"36","author":"Armand","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024031115352811800_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2018-02-811174","article-title":"Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil","volume":"132","author":"Herbaux","year":"2018","journal-title":"Blood"},{"issue":"25","key":"2024031115352811800_bib6","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET Phase II Randomized Trial","volume":"38","author":"Palma","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 16","key":"2024031115352811800_bib7","doi-asserted-by":"crossref","first-page":"7515","DOI":"10.1200\/JCO.2023.41.16_suppl.7515","article-title":"Response-adapted therapy (tx) with nivolumab plus brentuximab vedotin (nivo + BV) without autologous hematopoietic cell transplantation (auto-HCT) in children, adolescents, and young adults (CAYA) with low-risk relapsed\/refractory (R\/R) classic Hodgkin lymphoma (cHL): CheckMate 744","volume":"41","author":"Harker-Murray","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"2024031115352811800_bib8","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ijrobp.2023.06.206","article-title":"Consolidative radio therapy in place of autologous stem cell transplant in patients with low-risk relapsed\/refractory (R\/R) classic Hodgkin lymphoma (cHL) treated with nivolumab plus brentuximab vedotin: CheckMate 744","volume":"117","author":"Hoppe","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2024031115352811800_bib9","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/cncr.31114","article-title":"Long-term outcomes among two-year survivors of autologous hematopoietic cell transplant for Hodgkin and diffuse large B-cell lymphoma","volume":"124","author":"Myers","year":"2018","journal-title":"Cancer"},{"issue":"1","key":"2024031115352811800_bib10","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1186\/s12885-020-07561-2","article-title":"Improving outcomes after autologous transplantation in relapsed\/refractory Hodgkin lymphoma: a European expert perspective","volume":"20","author":"Sureda","year":"2020","journal-title":"BMC Cancer"},{"issue":"12","key":"2024031115352811800_bib11","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.bbmt.2013.09.018","article-title":"Simplified validated prognostic model for progression-free survival after autologous transplantation for Hodgkin lymphoma","volume":"19","author":"Hahn","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2024031115352811800_bib12","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1365-2141.2009.07727.x","article-title":"Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma","volume":"146","author":"Moskowitz","year":"2009","journal-title":"Br J Haematol"},{"issue":"18","key":"2024031115352811800_bib13","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2024031115352811800_bib14","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3816\/CLM.2004.n.017","article-title":"Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin\u2019s lymphoma","volume":"5","author":"Venkatesh","year":"2004","journal-title":"Clin Lymphoma"},{"issue":"8","key":"2024031115352811800_bib15","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.bbmt.2008.05.021","article-title":"Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant","volume":"14","author":"Smith","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2024031115352811800_bib16","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1200\/JCO.2007.13.2415","article-title":"Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin\u2019s lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"26","author":"Sureda","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2024031115352811800_bib17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2024031115352811800_bib18","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1182\/blood.2022019386","article-title":"Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed\/refractory classical Hodgkin lymphoma","volume":"142","author":"Armand","year":"2023","journal-title":"Blood"},{"issue":"suppl 17","key":"2024031115352811800_bib19","doi-asserted-by":"crossref","first-page":"LBA4","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4","article-title":"SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL)","volume":"41","author":"Herrera","year":"2023","journal-title":"J Clin Oncol"},{"issue":"14","key":"2024031115352811800_bib20","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.2004.12.170","article-title":"ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin\u2019s disease: long-term results","volume":"22","author":"Bonadonna","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"2024031115352811800_bib21","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","article-title":"Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin\u2019s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial","volume":"28","author":"Eich","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"2024031115352811800_bib22","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/blood-2018-03-837633","article-title":"Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines","volume":"132","author":"Dabaja","year":"2018","journal-title":"Blood"},{"issue":"19","key":"2024031115352811800_bib23","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa064601","article-title":"Chemotherapy plus involved-field radiation in early-stage Hodgkin\u2019s disease","volume":"357","author":"Ferm\u00e9","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"31","key":"2024031115352811800_bib24","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024031115352811800_bib25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0360-3016(96)00277-5","article-title":"High-dose therapy and autologous bone marrow transplantation for relapsed\/refractory Hodgkin\u2019s disease: the impact of involved field radiotherapy on patterns of failure and survival","volume":"36","author":"Poen","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"2024031115352811800_bib26","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1200\/JCO.2005.05.022","article-title":"Salvage radiotherapy in patients with relapsed and refractory Hodgkin\u2019s lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group","volume":"23","author":"Josting","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2024031115352811800_bib27","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.22.02355","article-title":"Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin lymphoma: final analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial","volume":"41","author":"Br\u00f6ckelmann","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2024031115352811800_bib28","doi-asserted-by":"crossref","first-page":"9080","DOI":"10.4081\/hr.2021.9080","article-title":"Immune checkpoint inhibitors in combination with radiotherapy as salvage treatment for relapsed\/refractory classical Hodgkin lymphoma: a retrospective analysis in 12 patients","volume":"13","author":"Lucchini","year":"2021","journal-title":"Hematol Rep"},{"issue":"2","key":"2024031115352811800_bib29","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.canrad.2018.05.002","article-title":"Anti-PD-1 immunotherapy in combination with sequential involved-site radiotherapy in heavily pretreated refractory Hodgkin lymphoma","volume":"23","author":"Qu\u00e9ro","year":"2019","journal-title":"Cancer Radiother"},{"issue":"32","key":"2024031115352811800_bib30","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"2024031115352811800_bib31","unstructured":"National Cancer Institute\n          . CD30 Receptor-Activated T-cells in Treating Patients with Relapsed or Refractory CD30+ Hodgkin Lymphoma or Non-Hodgkin Lymphoma. Accessed 21 June 2023. https:\/\/www.cancer.gov\/about-cancer\/treatment\/clinical-trials\/search\/v?id=NCI-2016-00789."},{"key":"2024031115352811800_bib32","unstructured":"Abscopal effect of radiotherapy and nivolumab in relapsed Hodgkin lymphoma after anti-PD1 therapy (AERN). ClinicalTrials.gov identifier: NCT03480334. Updated 13 September 2023. Accessed 21 June 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03480334."},{"key":"2024031115352811800_bib33","unstructured":"Pembrolizumab and involved site radiation therapy for early stage relapsed or primary refractory Hodgkin lymphoma. ClinicalTrials.gov identifier: NCT03179917. Updated 20 December 2023. Accessed 21 June 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03179917."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/5\/1250\/2217570\/blooda_adv-2023-011533-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/5\/1250\/2217570\/blooda_adv-2023-011533-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T15:36:01Z","timestamp":1710171361000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/5\/1250\/506932\/Patterns-of-progression-after-immune-checkpoint"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,1]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,3,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011533","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,1]]}}}